Arrowstreet Capital
VRDN icon

Arrowstreet Capital’s Viridian Therapeutics VRDN Stock Holding History

Arrowstreet Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20M Sell
972,939
-139,474
-13% -$2.98M 0.01% 814
2026
Q2 		$20.4M Buy
1,112,413
+1,089,134
+4,679% +$17.5M 0.01% 851
2026
Q1 		$455K Sell
23,279
-317,979
-93% -$9.44M ﹤0.01% 1685
2025
Q4 		$10.6M Buy
+341,258
New +$9.36M 0.01% 906

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Arrowstreet Capital's VRDN Position: Q3 2026 in Review

Arrowstreet Capital reduced its Viridian Therapeutics (VRDN) stake by 13% in Q3 2026, selling an estimated $2.98M and leaving 972,939 shares worth $20M. The position accounts for 0.01% of the portfolio, ranked #814.

Arrowstreet Capital first reported a position in VRDN in Q4 2025 and has held it in 4 quarters since. The position peaked at $20.4M in Q2 2026. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Arrowstreet Capital held 972,939 shares of Viridian Therapeutics worth $20M as of Q3 2026.
  • Arrowstreet Capital sold 139,474 Viridian Therapeutics shares in Q3 2026, an estimated $2.98M.
  • Viridian Therapeutics made up 0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #814 holding.
  • Arrowstreet Capital first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Arrowstreet Capital's Viridian Therapeutics position peaked at $20.4M in Q2 2026.
  • 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.